From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.

Slides:



Advertisements
Similar presentations
Date of download: 5/28/2016 From: When to Start Antiretroviral Therapy in Resource-Limited Settings Ann Intern Med. 2009;151(3): doi: /
Advertisements

Date of download: 5/31/2016 From: Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med. 2008;148(12): doi: /
Date of download: 6/1/2016 From: Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia Ann Intern Med. 2000;133(11): doi: /
Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/9/2016 From: Cost-Effectiveness of Preparticipation Screening for Prevention of Sudden Cardiac Death in Young Athletes Ann Intern Med.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Obstructive Sleep Apnea Treatment on Atrial.
Date of download: 6/21/2016 From: The Epidemiology of Prescriptions Abandoned at the Pharmacy Ann Intern Med. 2010;153(10): doi: /
Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.
Date of download: 6/22/2016 From: Prolonged Versus Standard-Duration Venous Thromboprophylaxis in Major Orthopedic Surgery: A Systematic Review Ann Intern.
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.
Date of download: 6/27/2016 From: Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost- Effectiveness Analysis.
Date of download: 6/29/2016 From: Predicting Future Functional Status for Seriously Ill Hospitalized Adults: The SUPPORT Prognostic Model Ann Intern Med.
Date of download: 7/2/2016 From: An Acute Change in Lung Allocation Score and Survival After Lung Transplantation: A Cohort Study Ann Intern Med. 2013;158(9):
Date of download: 7/5/2016 From: Sunscreen and Prevention of Skin Aging: A Randomized Trial Ann Intern Med. 2013;158(11): doi: /
Date of download: 7/9/2016 From: Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac.
Date of download: 7/10/2016 From: Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial.
Date of download: 9/17/2016 From: Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost- Effectiveness Analysis Ann.
Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):
Date of download: 9/17/2016 From: Polymerase Chain Reaction for the Diagnosis of HIV Infection in Adults: A Meta-Analysis with Recommendations for Clinical.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: An Improved Definition of Immune Heparin-Induced.
Date of download: 9/18/2016 From: Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal Ann Intern Med. 2013;158(1):1-9.
Date of download: 9/19/2016 From: The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and Satisfaction with Care Ann.
Date of download: 11/12/2016 From: Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseA Randomized,
From: Screening for Syphilis Infection in Pregnancy: U. S
Ann Intern Med. 2011;155(7): doi: / Figure Legend:
Ann Intern Med. 2010;153(7): doi: / Figure Legend:
From: Effects of Pulmonary Rehabilitation on Physiologic and Psychosocial Outcomes in Patients with Chronic Obstructive Pulmonary Disease Ann Intern Med.
Volume 355, Issue 9212, Pages (April 2000)
From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M
From: Effects of Low-Carbohydrate and Low-Fat DietsA Randomized Trial
Ann Intern Med. 2016;164(8): doi: /M Figure Legend:
From: Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern.
From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.
Ann Intern Med. 2014;160(11): doi: /M Figure Legend:
From: Pharmacologic Therapy for Type 2 Diabetes Mellitus
From: Wells Rule and d-Dimer Testing to Rule Out Pulmonary EmbolismA Systematic Review and Individual-Patient Data Meta-analysis Ann Intern Med. 2016;165(4):
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
Ann Intern Med. 1995;123(2): doi: / Figure Legend:
From: An Externally Validated Model for Predicting Long-Term Survival after Exercise Treadmill Testing in Patients with Suspected Coronary Artery Disease.
Copyright © 2008 American Medical Association. All rights reserved.
From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /
From: Population-Based Risk for Complications After Transthoracic Needle Lung Biopsy of a Pulmonary Nodule: An Analysis of Discharge Records Ann Intern.
Copyright © 2003 American Medical Association. All rights reserved.
From: The Evolving Diabetes Burden in the United States
Fig. 2. Comparative efficacy of thromboprophylaxis interventions in the prevention of deep vein thrombosis (DVT). (A) Estimated odds ratios (ORs) and 95%
From: Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States Ann Intern Med. 2013;158(2):84-92.
Ann Intern Med. 2009;150(11): doi: / Figure Legend:
From: Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical.
From: Treatment of Refractory Whipple Disease with Interferon-γ
From: Quantitative Synthesis in Systematic Reviews
From: Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy
From: Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal WomenA Randomized.
From: Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
Copyright © 2012 American Medical Association. All rights reserved.
Ann Intern Med. 2004;140(11): doi: / Figure Legend:
Ann Intern Med. 2004;140(11): doi: / Figure Legend:
From: A 10-Year Experience with Universal Health Insurance in Taiwan: Measuring Changes in Health and Health Disparity Ann Intern Med. 2008;148(4):
From: Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and Hyperlipidemia Ann Intern Med. 2012;156(11):
From: Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular DiseaseGrand Rounds Discussion From the Beth Israel Deaconess Medical.
Volume 373, Issue 9679, Pages (June 2009)
Ann Intern Med. 2009;151(9): doi: / Figure Legend:
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
Copyright © 2000 American Medical Association. All rights reserved.
From: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate.
From: Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment ProgramA Randomized Trial Ann Intern Med.
Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y
Volume 373, Issue 9679, Pages (June 2009)
Cost-Effectiveness of Strategies for Diagnosing Pulmonary Embolism Among Emergency Department Patients Presenting With Undifferentiated Symptoms  Ram.
Presentation transcript:

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann Intern Med. 1999;130(10):789-799. doi:10.7326/0003-4819-130-10-199905180-00002 Figure Legend: The cost-effectiveness decision model.DVTUFHLMWHPEAt left, a square node represents the decision to treat acute deep venous thrombosis ( ) with either unfractionated heparin ( ) or low-molecular-weight heparin ( ). In the primary analysis, low-molecular-weight heparin treatment always occurred in an inpatient hospital setting. In the secondary analysis, some patients were eligible for early discharge or outpatient treatment, as indicated by the first round uncertainty node. All patients were at risk for early complications. Probabilities for early complications depended on the type of treatment received. Two early complications, major bleeding and pulmonary embolism ( ), were potentially fatal. All patients who did not develop a fatal early complication were at risk for a fatal or nonfatal late complication. Late complications included episodes of recurrent deep venous thrombosis and pulmonary embolism that occurred more than 6 months after the initial episode of deep venous thrombosis, mild and severe postphlebitic syndrome, superficial venous thrombosis, cellulitis, venous ulcer, varicose veins, stasis dermatitis, and deep venous insufficiency. The diamond-shaped nodes at the end of each path in the decision tree represent both the costs and the health effects associated with the full sequence of events in that particular path. Date of download: 12/23/2017 Copyright © American College of Physicians. All rights reserved.

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann Intern Med. 1999;130(10):789-799. doi:10.7326/0003-4819-130-10-199905180-00002 Figure Legend: Tornado diagram showing the results of univariate sensitivity analyses.dashed vertical lineQALYThe solid vertical line represents the incremental cost-effectiveness of inpatient treatment with low-molecular-weight heparin relative to treatment with unfractionated heparin when all variables were set at their baseline value. Horizontal bars indicate the range in incremental cost-effectiveness ratios obtained by setting each variable at the lower and upper limit of its range and holding all other variables constant at their baseline value. Incremental cost-effectiveness ratios less than $0 ( ) indicate that treatment with low-molecular-weight heparin is cost saving. The cost-effectiveness of inpatient treatment with low-molecular-weight heparin was sensitive to only one variable: the effectiveness in preventing late complications. When other model variables were tested over a wide range of values, the cost-effectiveness ratio for inpatient treatment with low-molecular-weight heparin was always less than $25 000 per quality-adjusted life-year ( ) gained. Date of download: 12/23/2017 Copyright © American College of Physicians. All rights reserved.

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann Intern Med. 1999;130(10):789-799. doi:10.7326/0003-4819-130-10-199905180-00002 Figure Legend: Results of multivariate sensitivity analysis.circlesdiamondstrianglesQALYEach solid line indicates the incremental cost-effectiveness of inpatient treatment with low-molecular-weight heparin relative to unfractionated heparin at various levels of pharmacy costs for low-molecular-weight heparin. The middle line ( ) represents baseline assumptions about the effectiveness of low-molecular-weight heparin in preventing early complications. The upper ( ) and lower ( ) lines represent the incremental cost-effectiveness of low-molecular-weight heparin treatment at its lower and upper limits of effectiveness in preventing early complications. Vertical bars represent the effect of varying the cost of treating early complications by ±25%. A negative cost-effectiveness ratio indicates that low-molecular-weight heparin is a cost-saving strategy. The cost-effectiveness ratio for inpatient treatment with low-molecular-weight heparin was almost always less than $25 000 per quality-adjusted life-year ( ) except when low-molecular-weight heparin was assumed to be at the lower limit of effectiveness in preventing early complications and the pharmacy cost was $105 (125% of the baseline estimate) or greater. Date of download: 12/23/2017 Copyright © American College of Physicians. All rights reserved.